Clinical trials: Metastatic Breast Cancer (MBC)
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Scalp Cooling in MBC
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab…
- Trial name
- NCT04986579
- Testing
- Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Breast Cancer
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
To demonstrate the efficacy of sabizabulin in the treatment of ER+HER2- metastatic breast cancer (MBC) as measured by progression free survival (PFS) by RECIST v1.1.
- Trial name
- NCT05079360
- Testing
- Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
- Where
- 26 sites in United States
- Sponsor
- Veru Inc.
HER2-positive Metastatic Breast Cancer
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
This study evaluates the efficacy and safety of SRT combined with pyrotinib and capecitabine in the treatment of patients with HER2-positive advanced breast cancer patients with brain metastases.
- Trial name
- NCT05042791
- Testing
- radiation combined with pyrotinib and capecitabine
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Metastatic Breast Cancer
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy
Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v.
- Trial name
- BEVAPROS (NCT02329639)
- Testing
- genetic interaction analysis
- Where
- 2 sites in Italy
- Volunteers
- 307 people
- Sponsor
- University of Pisa
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
The goal of this national, multicenter single arm phase II clinical trial is to study the efficacy, safety and tolerability of the administration of Trastuzumab Deruxtecan (T-DXd) in HER2-positive locally advanced or metastatic…
- Trial name
- TRANSCENDER (NCT05744375)
- Testing
- Trastuzumab deruxtecan
- Where
- 19 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Spanish Breast Cancer Research Group
Metastatic Breast Cancer
Observation of Medical Treatments in MBC HER2-negative Patients
While therapeutic strategies for HER2-positive breast cancer are well defined, there is not a standard strategy for HER2-negative tumors.
- Trial name
- AMBRA (NCT02365831)
- Testing
- Observation of treatment management
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Consorzio Oncotech
Breast Cancer
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
- Trial name
- NCT03695341
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
This is an international, open-label, non-controlled, multicenter phase II clinical trial with two different primary objectives: a biological and a clinical objective.
- Trial name
- BioPER (NCT03184090)
- Testing
- Palbociclib, Endocrine therapy (non IMP)
- Where
- 15 sites in Italy, Spain
- Volunteers
- 33 people
- Sponsor
- MedSIR
Metastatic Breast Cancer
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Despite recent advances for the treatment of post-menopausal hormone receptor-positive BC, in the last decade there was no major improvement of hormonal therapy specifically for premenopausal metastatic breast cancer.
- Trial name
- NCT02592746
- Testing
- Palbociclib, Exemestane, Leuprolide Acetate
- Where
- 2 sites in South Korea
- Volunteers
- 182 people
- Sponsor
- Samsung Medical Center
Metastatic Breast Cancer
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Recent clinical studies have shown that the combination of lapatinib and trastuzumab has superior antitumor activity compared to either single drug in both neoadjuvant and metastatic setting and is well tolerated.
- Trial name
- NCT02238509
- Testing
- Lapatinib, Trastuzumab
- Where
- 36 sites in Italy
- Volunteers
- 154 people
- Sponsor
- Consorzio Oncotech
Breast Cancer, Prostate Cancer
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh peripheral blood mononuclear cells (HER2 FPBMC) for patients with metastatic breast…
- Trial name
- NCT07441889
- Testing
- HER2 FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Metastatic Colorectal Cancer, Metastatic Breast Cancer
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
This is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer.
- Trial name
- BRECOL (NCT01733628)
- Where
- 10 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
HER2-positive Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
To evaluate the efficacy,safety and immunogenicity of TQ-B211 plus docetaxel versus Herceptin® plus docetaxel in Patients with HER2-positive metastatic breast cancer.Trastuzumab plus docetaxel was chosen as the comparator in the…
- Trial name
- NCT04385563
- Testing
- TQ-B211, Herceptin®, docetaxel
- Where
- 2 sites in China
- Volunteers
- 338 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER 2 Negative Breast Cancer
A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
This study is looking at a new combination of two drugs-eribulin and anlotinib-for patients with HER2-negative advanced breast cancer.
- Trial name
- MBC-EA (NCT07520760)
- Testing
- Eribulin in Combination with Anlotinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
The goal of this research study is to determine if the investigators can predict which participants will respond to endocrine therapy and a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor for metastatic breast cancer and…
- Trial name
- NCT03439735
- Testing
- Endocrine Therapy and a CDK 4/6 inhibitor
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.
- Trial name
- NCT04796324
- Testing
- Ixabepilone Injection
- Where
- 19 sites in Belgium, Finland and 5 more
- Volunteers
- 13 people
- Sponsor
- Allarity Therapeutics
ER-Positive HER2-Negative Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in…
- Trial name
- SERENA-6 (NCT04964934)
- Testing
- AZD9833, Anastrozole, Letrozole
- Where
- 264 sites in United States, Australia and 21 more
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
Breast Cancer
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
Study on the Value of Non-invasive Dual-Pet(18F-FES PET and 68Ga-HER2-Affibody PET) Information in Subtype of Metastatic Breast Cancer
- Trial name
- NCT04758416
- Testing
- biopsy or surgical pathology in metastases, 68Ga-HER2 affibody,18F-FDG, 18F-FES
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fudan University